Zai Lab LTD 8-K filings

Zai Lab announced its second quarter 2026 financial results, highlighting total revenues of $106.3 million and significant progress in its oncology and immunology pipelines, with key clinical and regulatory milestones anticipated.

Zai Lab Limited announced that President and Chief Operating Officer Josh Smiley will step down from his roles effective May 18, 2026.

Zai Lab reported Q1 2026 results with a 6% revenue decrease year-over-year, primarily due to ZEJULA sales, while highlighting advancements in its oncology and immunology pipeline.

Zai Lab Limited announced robust financial results for the fourth quarter and full year 2025, driven by product revenue growth and significant pipeline advancements, while reducing net losses.

Zai Lab Limited reported a 14% year-over-year revenue increase to $116.1 million in Q3 2025, alongside a 28% improvement in operating loss, and revised full-year revenue guidance to at least $460 million.

Zai Lab Limited has secured a revolving credit facility of up to RMB300 million (approximately $42.1 million) for its China operations, guaranteed by the parent company.

Zai Lab Limited reported a significant reduction in its second-quarter 2025 operating loss and strong revenue growth, driven by record VYVGART utilization, while reaffirming full-year guidance.

Zai Lab Limited announced that all proposals, including the re-election of its board of directors and approval of share issuance and repurchase mandates, were passed at its 2025 Annual General Meeting of Shareholders.

Zai Lab reports a 22% year-over-year revenue increase to $106.5 million in Q1 2025 and reaffirms its full-year revenue guidance of $560 million to $590 million.

Zai Lab announces a 66% increase in fourth-quarter revenue and a 50% increase in full-year revenue, driven by strong product sales and pipeline advancements, with expectations to reach profitability in Q4 2025.

Zai Lab Limited has entered into a guarantee contract and a working capital loan contract with Bank of Communications for a revolving credit facility of up to RMB 300 million to support its working capital needs in mainland China.

Zai Lab has announced the pricing of a public offering of 7,843,137 American Depositary Shares (ADSs) at $25.50 per ADS, expected to raise approximately $200 million in gross proceeds.

Zai Lab Limited has updated its risk factors disclosure, highlighting concerns related to data privacy, intellectual property, and anti-corruption laws, particularly in China.

Zai Lab announced a 47% year-over-year increase in net product revenue for the third quarter of 2024, driven by strong sales of VYVGART and advancements in its pipeline.

Zai Lab announced a 45% year-over-year increase in net product revenue for the second quarter of 2024, primarily driven by the successful launch of VYVGART.

Zai Lab Limited has secured a debt facility of up to RMB 250 million with China Merchants Bank to support its working capital needs in mainland China.

Zai Lab Limited's shareholders approved the 2024 Equity Incentive Plan and re-elected all nominated directors at the 2024 Annual General Meeting.

Zai Lab's Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases, Dr. Harald Reinhart, will retire, and Dr. Rafael Amado will expand his role to lead all Global R&D.

Zai Lab's first quarter 2024 results show a 39% year-over-year revenue increase, fueled by the launch of VYVGART and strong performance across its portfolio.

Zai Lab announced a 25% year-over-year increase in product revenue for 2023, driven by the launch of VYVGART and strong performance across its portfolio, while also highlighting progress in its clinical pipeline.

Zai Lab has entered into multiple debt financing agreements with Chinese banks, securing over $190 million to support its working capital needs in mainland China.